The use of CMP-001, an intratumoral toll-like receptor 9 (TLR9) agonist, is capable of triggering durable responses when used in combination with pembrolizumab (Keytruda) for patients with PD-1 resistant metastatic melanoma according to results from a phase Ib study presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting (SITC 2019).1
Publications
Melanoma Journal Articles for October 2019
Please click on the link to see a list of melanoma journal citations that crossed the MRV desk this month.
Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition
Among women enrolled in the European Prospective Investigation into Cancer and Nutrition, a prospective cohort analysis started in 1992 in 10 European countries, researchers investigated the links between the use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk. A total of 334,483 women with 1,696 melanoma cases were identified over 1992–2015, including 134,758 postmenopausal women with 770 cases
Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy
A total of 103 individuals with immunotherapy for metastatic melanoma were randomly distributed into training (n?=?69) and validation cohort (n?=?34) in order to recognize predictive clinical and CT imaging biomarkers and evaluate their predictive capability about overall survival (OS) and treatment response in individuals with metastatic melanoma who were undergoing immunotherapy.